Expanded Access Allows Compassionate Use of Investigational Drugs When Few Options Exist

When standard treatments fall short, expanded access programs can open doors that otherwise stay closed. For patients facing hepatocellular carcinoma (HCC) or other serious conditions, these programs may offer a meaningful — sometimes lifesaving — path forward.

Understanding how they work helps you act faster when your patients need it most.

What Is Expanded Access?

Expanded access allows patients to use investigational drugs outside of a clinical trial. These are medications still under study — not yet fully approved by the U.S. Food and Drug Administration (FDA). The programs are designed specifically for patients with serious or life-threatening conditions who have exhausted approved treatment options.

You may also hear the term "compassionate use." The FDA uses both terms, and they refer to the same framework.

The programs bridge the gap between active clinical investigation and full regulatory approval. For patients who have tried everything else, that bridge can be the difference between hope and none.

Who Qualifies?

Not every patient is eligible. Three core criteria must be met.

The patient must have a serious or life-threatening condition. There must be no satisfactory approved alternatives. And the potential benefit of the investigational drug must outweigh the risks.

Physicians carry a significant documentation responsibility. A thorough record of the patient's medical history, current condition, prior treatments and clinical rationale is required to support an application. Incomplete documentation is one of the most common reasons applications stall.

Types of Expanded Access Programs

The FDA recognizes three distinct program types. Understanding the difference matters when you are evaluating options for your patient.

Individual patient access is for a single patient with a specific, documented need. This is the most common pathway physicians pursue.

Intermediate-size patient population access applies when a small group of patients with similar conditions may benefit from the same investigational treatment. This pathway is often used when a drug is in later-stage trials and early evidence supports broader access.

Large patient population access — sometimes called a treatment protocol — functions similarly to a clinical trial in scale. It is typically used when widespread access is warranted and the drug is moving toward approval.

Identifying the right category early prevents delays and sets the application up for a faster review.

The Process of Expanded Access

Initial consultation. The process starts with a conversation. You assess whether expanded access is appropriate, review the patient's full medical history and explain the potential risks and benefits. Informed consent is not a formality here — patients facing serious conditions deserve a clear-eyed picture of what investigational treatment involves.

Application submission. An application is submitted to the FDA with detailed patient information and supporting documentation from the treating physician. The process requires careful attention to detail. Errors or omissions slow everything down.

Review and approval. The FDA reviews the application and grants approval if the criteria are met. Complexity affects timeline, but prompt submission and follow-up help move things along. For urgent cases, the agency can act within days.

Drug delivery. Once approved, the drug must be delivered promptly. Coordination between you, the healthcare facility and the manufacturer is essential. Delays at this stage directly affect patient outcomes.

Monitoring and reporting. Ongoing monitoring is required throughout treatment. You must report any adverse effects to the FDA. Regular follow-ups confirm whether the treatment is working and flag safety concerns early. The data you collect also contributes to broader medical knowledge and supports the drug's path to full approval.

FDA's Role

The FDA reviews and approves all expanded access requests. That process includes evaluating the scientific evidence behind the drug, assessing the balance of benefit and risk for the intended patient population, and verifying that appropriate safeguards are in place.

The review is not a rubber stamp. The FDA maintains rigorous standards, and its oversight is designed to protect patients — not slow them down. In practice, the agency approves the vast majority of individual patient requests, often within days for urgent cases.

Physicians work directly with the drug manufacturer as well. The company must agree to provide the investigational drug and cooperate with the application process. For more information, visit the FDA's Expanded Access page.

What Physicians Need to Know

Your role in expanded access goes well beyond filing paperwork. You are the patient's primary advocate throughout the entire process.

Start with the manufacturer. Before filing with the FDA, confirm the drug company is willing to provide access. Without that agreement, the application cannot move forward.

Document thoroughly. The FDA needs a clear clinical picture — diagnosis, treatment history, current status and your rationale for why this specific drug is appropriate for this specific patient.

Consult your institution's IRB. Depending on the type of access and your facility's policies, Institutional Review Board (IRB) oversight may be required or recommended. Check early.

Educate your patient. You must explain the potential risks and benefits clearly. Informed consent is both a legal and ethical requirement.

Monitor and report outcomes. Your obligation does not end at approval. Ongoing monitoring, adverse event reporting and regular follow-ups are required for the duration of treatment.

Act early. Expanded access is not a last-minute option. The earlier in a patient's treatment trajectory you consider it, the more time you have to navigate the process without crisis-driven pressure.

Hepatocellular Carcinoma and Why It Qualifies

HCC is the most common form of primary liver cancer. It develops in hepatocytes — the main functional cells of the liver — and is frequently linked to chronic liver disease, including cirrhosis and hepatitis B and C infections.

HCC often progresses quickly and has limited treatment options in advanced stages. That profile makes it one of the conditions where expanded access is most relevant. When approved therapies stop working, investigational drugs in expanded access programs can offer a legitimate next step rather than no step at all.

Why Expanded Access Matters for HCC Patients

Addressing unmet needs. HCC patients in advanced stages frequently exhaust approved options faster than new treatments reach the market. Expanded access fills that gap directly. Early access to investigational therapies can meaningfully affect both survival and quality of life.

Clinical benefits. Data from expanded access programs have shown measurable outcomes for some HCC patients, including tumor response and extended survival in cases where standard treatments had failed. These results strengthen the clinical rationale for pursuing the programs and contribute evidence toward eventual approval.

Supporting research and development. Every expanded access case generates real-world data. That information helps researchers understand how a drug performs outside controlled trial conditions, identify side effects that may not have surfaced in trials and refine treatment protocols. The data you report as a treating physician directly accelerates the approval process for future patients.

Challenges and Practical Solutions

Expanded access is not without friction. Regulatory requirements are detailed, drug availability is not guaranteed and the timeline can feel at odds with a patient's urgency.

Manufacturers are not obligated to provide access, and some decline. Staying current on which investigational drugs are available — and which companies have established expanded access programs — reduces the chance of a dead end.

Streamlined FDA application processes and improved communication between regulators, manufacturers and healthcare providers have made the pathway more navigable in recent years. Working with a physician who has prior expanded access experience, or engaging your institution's research office early, can make a significant difference.

Advocate 

Expanded access programs exist because the FDA recognizes that some patients cannot wait for full approval. For physicians treating patients with HCC or other serious conditions, these programs represent a legitimate, structured option — not a workaround.

Understanding the framework means you are better prepared to advocate for your patients when the standard toolkit runs out.

Does your practice have a process in place for evaluating expanded access options before a patient reaches end-of-line treatment?